Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Proteus S.A.
FDA has approved Abilify MyCite, a treatment for some psychiatric conditions that integrates a drug with a sensor that records when the medication is taken. The goal is to track medication compliance. It is an important regulatory milestone for the nascent field of digital medicine, but many questions about the market remain.
Astellas will pay Chromocell $15m up front and could spend more than $500m on milestone fees under a license and collaboration agreement for Nav1.7 antagonists, including lead drug candidate CC8464 and backup compounds, for the treatment of neuropathic pain and other conditions.
An emerging market in stroke rehabiliatation, and advancing the diagnosis and treatment of ophthalmic diseases.
- Other Names / Subsidiaries